<DOC>
	<DOCNO>NCT00687453</DOCNO>
	<brief_summary>To compare efficacy safety once-nightly insulin glargine versus twice-daily NPH insulin ethnic minority type 2 diabetic patient inadequately treat once-nightly NPH insulin alone .</brief_summary>
	<brief_title>Insulin Glargine Versus Twice-Daily NPH</brief_title>
	<detailed_description>Insulin glargine long action compare NPH insulin , whether result improve control compare twice-daily NPH insulin know used low-income ethnic minority patient . This study investigate whether insulin glargine may less effective safe twice-daily NPH insulin population .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Male female , age 1875 Type 2 diabetes diagnose least 1 year Inadequate glycemic control ( hemoglobin A1c â‰¥ 7.5 % ) stable maximumtolerated dos sulfonylurea , metformin thiazolidinedione , plus single bedtime injection NPH insulin Except subject 's current bedtime NPH insulin , past history chronic insulin use ( treatment gestational diabetes hospitalization less 1 week duration ) Average fast plasma glucose level &lt; 130 mg/dL without fast hypoglycemia Hemoglobin A1c 7.5 % 12 % Body mass index ( BMI ) 20 40 kg/m2 History confirmed ( clinical suspicion ) type 1 diabetes Female subject childbearing potential sexually active use reliable form contraception . Current pregnancy lactation . Subjects intensive insulin therapy contraindicate Subjects advance proliferative diabetic retinopathy Subjects unable stay consistent daily meal schedule History clinically significant renal , hepatic , cardiovascular , neurological , endocrinological major systemic disease , opinion investigator , may make implementation protocol interpretation data difficult . Subjects likely require initiate therapy drug may interfere glucose metabolism course study Subjects another investigational study receive another investigational medication within 30 day study entry Subjects unable unwilling comply component study protocol , include contact investigator specify time attend scheduled followup visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Glargine</keyword>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Basal insulin</keyword>
</DOC>